Literature DB >> 3401929

Tolerance induction by a poorly arthritogenic collagen II can prevent collagen-induced arthritis.

R F van Vollenhoven1, C Nagler-Anderson, A Soriano, G W Siskind, G J Thorbecke.   

Abstract

Collagen type II (CII)-induced arthritis (CIA) can be induced in 78% of B10.RIII mice (H2r) by intradermal (id) immunization with CII of bovine origin in complete Freund's adjuvant (CFA), whereas immunization with CII of chick origin induces arthritis in less than 5% of these mice. Nevertheless, tolerization of B10.RIII mice with intravenously injected chick CII renders the animals resistant to induction of CIA by immunization with bovine CII. Such tolerization can be achieved either by intravenous injection of 500 micrograms chick CII 1 week prior to immunization with bovine CII in CFA or by such an intravenous injection of chick CII 2 weeks after immunization with bovine CII in CFA. Postimmunization treatment results in a significant decrease in the concentration of antibody to bovine CII. Preimmunization administration of chick CII causes a marked decrease in the antibody reactive with chick CII without a significant effect on the anti-bovine CII antibody concentration. In DBA/1 mice, a strain in which both bovine CII and chick CII can induce a high incidence of the disease, intravenous injection of bovine CII can also prevent arthritis induced by chick CII, even when given 7 or 14 days after immunization. The fact that chick CII as tolerogen is quite effective in preventing arthritis in B10.RIII mice, while as immunogen it is very ineffective in inducing arthritis in this strain, may be interpreted as evidence for interaction between different epitopes on CII in the pathogenesis of CIA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401929     DOI: 10.1016/0008-8749(88)90169-4

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  In memorium G. Jeanette Thorbecke, 1929-2001.

Authors:  Vincent K Tsiagbe; Susan Zolla-Pazner; Richard Coico; Nicholas M Ponzio
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 2.  Possibilities for the immunotherapy of rheumatoid arthritis.

Authors:  F C Breedveld; R R De Vries
Journal:  Clin Rheumatol       Date:  1990-06       Impact factor: 2.980

3.  Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice.

Authors:  L K Myers; D D Brand; X J Ye; M A Cremer; E F Rosloniec; M Bodo; J Myllyharju; T Helaakoski; M Nokelainen; T Pihlajaniemi; K Kivirikko; C L Yang; L Ala-Kokko; D J Prockop; H Notbohm; P Fietzek; J M Stuart; A H Kang
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

4.  Identification and characterization of a major tolerogenic T-cell epitope of type II collagen that suppresses arthritis in B10.RIII mice.

Authors:  H Miyahara; L K Myers; E F Rosloniec; D D Brand; J M Seyer; J M Stuart; A H Kang
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

5.  Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice.

Authors:  Fumiaki Kojima; Mohit Kapoor; Lihua Yang; Erica L Fleishaker; Martin R Ward; Seetha U Monrad; Ponnappa C Kottangada; Charles Q Pace; James A Clark; Jerold G Woodward; Leslie J Crofford
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

6.  Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice.

Authors:  G J Thorbecke; R Shah; C H Leu; A P Kuruvilla; A M Hardison; M A Palladino
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

7.  Gene Therapy Induces Antigen-Specific Tolerance in Experimental Collagen-Induced Arthritis.

Authors:  Sara Tengvall; Tove Eneljung; Pernilla Jirholt; Olof Turesson; Kajsa Wing; Rikard Holmdahl; Jan Kihlberg; Anna Stern; Inga-Lill Mårtensson; Louise Henningsson; Kenth Gustafsson; Inger Gjertsson
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.